Last reviewed · How we verify
Ilevro
Ilevro, marketed by Carolina Eyecare Physicians, LLC, is a drug with a key composition patent expiring in 2028. The primary strength of Ilevro lies in its current market presence, leveraging the patent protection to maintain exclusivity. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Ilevro |
|---|---|
| Also known as | Nepafenac 0.3% |
| Sponsor | Carolina Eyecare Physicians, LLC |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy (PHASE4)
- Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal Photocoagulation (PHASE2)
- DSAEK/DMEK and Cystoid Macular Edema - the Role for Topical NSAIDs (Nepafenac) (DMEC) (PHASE4)
- Cataract Surgery and Inflammation - the Role for Preoperative NSAIDs (Pre-CIN) (PHASE4)
- Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension (PHASE3)
- Macular Edema Nepafenac vs. Difluprednate Uveitis Trial (PHASE4)
- Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% (PHASE4)
- Post Intravitreal Injection Topical NSAID vs. Patching (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |